Revenue
Margin
Demand
Guidance
Tone
Metrics raised 1
- Beyond FY27 combined business volume growth raised to mid-teens CAGR over next couple of years, including new launches from FY28 onward
Event Participants
Executives
4 Amit Dahanukar, Ameya Deshpande, Rajesh Choudhary, Sanaya Dahanukar
Analysts
6 Abneesh Roy, Heer Gogri, Nitin Gupta, Sucrit Patil, Vaibhav Gupta, Vijay Jangir
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Overall Volumes | 172% YoY growth, 9% QoQ growth | Imperial Blue volumes grew 18% QoQ to 5.4 million cases; MHB grew 7% YoY; achieved highest ever monthly volume of 3.4 million cases in June 2026 |
| Net Revenue | ₹1,046 crores | Grew 166% YoY; adjusted for subsidy, revenue was ₹1,026 crores with 189% YoY growth |
| NSR (Net Sales Realization) | ₹1,183 per case | Up 1.5% QoQ from ₹1,166 per case in Q4 FY26 and 5.3% YoY from ₹1,123 per case in Q1 FY26; NSR calculation now adjusted for cash discounts, breakages, and wastages |
| Gross Profit (Adjusted for Subsidy) | ₹432 crores | Margin at 42.1% vs 45.2% in Q4 FY26; excluding inflationary pressures, margin would have been ~44.5%; impacted by glass/packaging cost inflation, partly offset by softer ENA prices |
| EBITDA | ₹169 crores | Grew 79% YoY at 16.1% margin; adjusted for subsidy, EBITDA was ₹148 crores with 14.5% margin; excluding inflationary pressures, margin would have been ~17% |
| PAT (Adjusted for Exceptional Items & Amortization) | ₹96 crores | Grew 9% YoY at 9.4% margin; adjusted for subsidy, PAT was ₹76 crores with 7.4% margin; excluding inflation and subsidy impact, margin would have been ~10% |
| Exceptional Expense | ₹30 crores | Predominantly TSMA fees and integration-related expenses in Q1 FY27 |
| Gross Debt | ₹2,241 crores | As of June 30, 2026; increase driven by working capital cycle investment |
| Net Debt | ₹2,100 crores | As of June 30, 2026; target is ~₹1,700 crores by March 2027; term debt of ~₹2,000 crores structured with ~80% of payments in years 5 and 6 with 2-year moratorium |
| Employee Strength | 850+ people | Scaled from ~350 pre-acquisition to 850+ as of March 31, 2026, primarily feet-on-ground sales roles across North, West, Central, and East India |
Geographic & Segment Commentary
- South India: Tilaknagar is the largest P&A player overall with 40% market share ex-Tamil Nadu; emerged as the largest IMFL player in Telangana in June 2026; South saw the most seamless IB integration transition given existing scale and distribution strength; market share improvements exceeded other regions.
- North India: Imperial Blue reintroduced in Delhi in July 2026; historical peak volume in Delhi was ~0.5 million cases (pre-COVID, FY20); management expects to reach those levels within 12-18 months; team and manufacturing footprint scaled up across the region.
- Maharashtra (West): IB market share expanding in the state; MML category stable at ~6-7 lakh cases per month industry-wide; Tilaknagar inching up market share at relevant price points.
- Tamil Nadu: Currently less than 0.5 million cases annually for Tilaknagar; Tamil Nadu is the largest brandy market in India at ~50 million cases; potential upside if new government opens up market or allows imports; monitoring policy changes.
- Karnataka: Post price reduction reforms, good volume uptake and significant market share improvement in the operating segment; competitive dynamics evolving with reduced pricing slabs.
- House of TI (Luxury & Super Premium): Expanded presence of Monarch Legacy Edition Brandy, Seven Islands Pure Malt Whisky, and Samsara Gin in West Bengal during Q1; SSL (Spaceman Spirits) more than doubled sales YoY; growth led by Samsara Pink and new Indian flavor variants (Jamun & Pink Salt, Raw Mango & Jalapeno); launched House:Pour Picante in agave/tequila RTD space.
Company-Specific & Strategic Commentary
- Imperial Blue Integration: 90% of IB business transitioned to Tilaknagar-operated units; only 1 state remains under TSMA with outer transition date of March 2027; sales integration completed by February 2026, manufacturing integration by April 2026; market share improved in all states post-acquisition vs. exit-period averages.
- A&SP Reinvestment: Activations carried out in 28,000 outlets during Q1 with consistent on-ground communications; company increasing A&SP reinvestment rates to compete in the increasingly active deluxe whisky segment.
- Strategic Investments: Doubled down on Bartisans investment, increasing stake from 36.2% to 41.5%; proceeds to fund quick commerce expansion, product/packaging innovation, and collaborative launches with TI.
- Supply Chain Optimization: Identified benefits expected to expand margins on acquired business by 250-400 bps and consolidated margins by ~250 bps; Prag Distillery savings ~60-70% baked into Q1 numbers with full benefit yet to reflect.
- Portfolio Expansion: Vacant spaces in portfolio to be addressed with new launches over next 12-36 months; FY28 onwards launches expected to drive mid-teens volume CAGR through FY29; leveraging pan-India distribution for premium and luxury portfolio rollout.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Combined Business Volume Growth (FY27) | High single-digit to low double-digit | Maintained guidance for current fiscal; IB acquired at ~21.5 million cases base; expects to end FY27 with double-digit volume growth for IB |
| Combined Business Volume Growth (Beyond FY27) | Mid-teens CAGR over next couple of years | Upgraded guidance including new launches planned from FY28 onwards; revenue expected to grow ~300 bps higher than volume growth |
| Consolidated EBITDA Margin (FY27) | Improvement from 15.5% base (Q4 FY26) | Q2 margins expected in similar range to Q1 due to incremental A&SP reinvestments; significant uptick expected in Q3 and Q4 due to seasonality |
| Consolidated EBITDA Margin (FY29) | 16%-18% with upward bias | Driven by supply chain optimization (250-400 bps on acquired business, ~250 bps consolidated), operating leverage, and economies of scale |
| Net Debt-to-EBITDA | Below 1.0x by March 2029 | Disciplined debt management and working capital investments; net debt target of ~₹1,700 crores by March 2027, a ~₹400 crore reduction from Q1 FY27 |
| Telangana Price Increase | 150-200 bps incremental margin impact (annualized) | Expected soon; 3 years since last price increase; active discussions with government underway |
| Delhi IB Volume Recovery | ~0.5 million cases in 12-18 months | IB reintroduced in Delhi in July 2026; historical peak was slightly above 0.5 million cases pre-COVID (FY20) |
Risks & Constraints
| Risk | Context |
|---|---|
| Packaging Cost Inflation | Geopolitical tensions driving inflationary pressures across packaging inputs, particularly glass; impacted gross margins by ~240 bps in Q1 (42.1% vs 45.2% in Q4 FY26); management assumes inflation remains status quo for margin guidance; mitigants include ENA price softness, state price increases, and supply chain optimization |
| Competitive Intensity in Deluxe Whisky | Increased activity by all participants in the IB price segment after prolonged inactivity; ICONiQ White growing at 50% and McDowell's increasing scotch presence; management viewing this as positive for overall category growth; Tilaknagar increasing A&SP reinvestment to compete |
| TSMA Transition Risk | 1 state still under TSMA with outer date of March 2027; Odisha, Punjab, and Uttarakhand faced TSMA-related disruptions in Q1; full operational control pending for remaining state |
| Regulatory/Policy Risk | Tamil Nadu market remains closed to imports; any policy change under new government could be a significant opportunity or risk; Telangana price increase pending for 3 years; state-level pricing and regulatory changes remain an ongoing variable |
| Debt and Working Capital | Net debt at ₹2,100 crores post-acquisition; term debt of ~₹2,000 crores with moratorium structure provides near-term cushion but elevated leverage levels require disciplined reduction; target net debt-to-EBITDA below 1.0x only by FY29 |
Q&A Highlights
IB Integration & State-Level Performance
- Question: Which states are seeing more traction vs. challenges for IB, and what is the Karnataka competitive dynamic post-reforms? (Abneesh Roy)
- Answer: Post price reduction in Karnataka, good volume uptake and significant market share improvement in the operating segment. South India overall saw the most seamless transition given pre-existing scale. Market share has improved in all states without exception vs. exit-period averages. Improvements seen across North, East, and West (Maharashtra) as well. (Amit Dahanukar, Ameya Deshpande)
Delhi Re-entry & Team Scale-Up
- Question: What was IB's peak market share/size in Delhi, and when will it be recovered? Is the pan-India team scale-up complete? (Abneesh Roy)
- Answer: Team scale-up fully completed — from ~350 people pre-acquisition to 850+ as of March 31, 2026, with additions across sales and manufacturing footprint in North, West, Central, and East India. Delhi peak volume was ~0.5 million cases (pre-COVID, FY20); expected to recover within 12-18 months. (Amit Dahanukar, Rajesh Choudhary)
TSMA Disruptions & Competitive Dynamics
- Question: Were Odisha, Punjab, and Uttarakhand disruptions specific to IB or the entire portfolio, and how is competition evolving in the IB price segment? (Nitin Gupta)
- Answer: Disruptions were predominantly IB-specific and TSMA-related. Competitive intensity in the deluxe whisky segment is increasing — ICONiQ White at 50% growth, McDowell's strengthening scotch presence. Management views this as positive for category growth after prolonged inactivity. Tilaknagar increasing A&SP reinvestment with activations in 28,000+ outlets. (Ameya Deshpande, Amit Dahanukar)
Margin Recovery Timeline
- Question: How soon can the 15.5% EBITDA margin baseline be recovered given packaging inflation? (Nitin Gupta)
- Answer: Margin improvement beyond 15.5% assumed with inflation at status quo. Q2 margins expected in similar range to Q1 due to incremental A&SP reinvestments. Significant margin uptick expected in Q3 and Q4 driven by seasonality (largest quarters by saliency). (Ameya Deshpande)
Long-Term Strategy & Portfolio Build-Out
- Question: What is the 3-4 year strategic plan beyond IB integration? (Nitin Gupta)
- Answer: FY27 focused on IB integration and distribution widening. New launches planned over next 12-36 months to fill portfolio gaps, driving mid-teens volume CAGR through FY29. Premium portfolio (House of TI, Spaceman Spirits) to be leveraged through expanded distribution infrastructure. Volume growth guidance upgraded to mid-teens beyond FY27 including new launches from FY28. (Amit Dahanukar, Ameya Deshpande)
IB Volume Run Rate & Telangana Pricing
- Question: What is the expected QoQ run rate for IB volumes, and are price increases expected from Telangana? (Heer Gogri)
- Answer: Full-year IB growth expected to be double-digit from the ~21.5 million cases base at acquisition. Telangana price increase expected soon — 3 years since last increase, active discussions with government underway. Expected impact: 150-200 bps incremental margin on annualized basis. (Amit Dahanukar, Ameya Deshpande)
Prag Distillery Savings & MML Competition
- Question: Are Prag Distillery cost savings reflecting in Q1 margins, and what is the current utilization? How is MML category competition in Maharashtra? (Vijay Jangir)
- Answer: ~60-70% of Prag Distillery bottling benefits already baked into Q1 numbers; full benefit yet to reflect. MML category stable at ~6-7 lakh cases per month industry-wide with no significant movement; Tilaknagar expanding market share in Maharashtra with IB performing well. (Ameya Deshpande)
Tamil Nadu Market Opportunity
- Question: How large is the Tamil Nadu market for Tilaknagar, and what is the impact of potential route-to-market changes? (Vaibhav Gupta)
- Answer: Tamil Nadu business currently less than 0.5 million cases annually. Tamil Nadu is the largest brandy market in India at ~50 million cases. Monitoring policy changes under new government; if imports allowed or market opens up, Tilaknagar could be a significant beneficiary given its brandy portfolio strength. (Amit Dahanukar)
Execution Priorities & Risk Management
- Question: What are the top execution priorities and biggest risks? How are margins, cash flow, and balance sheet being managed? (Sucrit Patil)
- Answer: Priorities are: (1) IB integration — already 90% complete within 4 months; (2) widening/deepening IB distribution with A&SP reinvestment; (3) building luxury portfolio via House of TI. Key risk is inflation, mitigated by state price increases and supply chain optimization (250-400 bps on acquired business, ~250 bps consolidated). Term debt of ~₹2,000 crores structured with ~80% of payments in years 5-6 with 2-year moratorium. Net debt target: ₹1,700 crores by March 2027. (Amit Dahanukar, Rajesh Choudhary, Ameya Deshpande)
Key Takeaway
Tilaknagar Industries delivered a strong Q1 FY27 with overall volumes growing 172% YoY and 9% QoQ, driven by Imperial Blue which reached 5.4 million cases, and achieved its highest ever monthly volume of 3.4 million cases in June 2026. Net revenue stood at ₹1,046 crores (166% YoY growth), while adjusted EBITDA was ₹148 crores at 14.5% margin, compressed by packaging cost inflation (particularly glass) which reduced margins by ~240 bps QoQ, partially offset by softer ENA prices. The IB integration is 90% complete with only one state remaining under TSMA (target: March 2027), and market share has improved across all states post-acquisition. Management is focused on four strategic pillars: double-digit volume growth, EBITDA margin expansion to 16%-18% by FY29 via supply chain optimization (250-400 bps on acquired business), net debt reduction to ~₹1,700 crores by March 2027 with leverage below 1.0x by FY29, and leveraging pan-India distribution for premium/luxury portfolio expansion. Volume growth guidance has been upgraded to mid-teens CAGR beyond FY27 including new launches from FY28. Key watch points include packaging inflation trajectory, competitive intensity in the deluxe whisky segment, TSMA transition completion, and regulatory developments in Tamil Nadu and Telangana, with the latter's anticipated price increase offering 150-200 bps annualized margin upside.